<DOC>
	<DOCNO>NCT00068471</DOCNO>
	<brief_summary>RATIONALE : Anidulafungin may effective prevent fungal infection immunocompromised child neutropenia . PURPOSE : This phase I/II trial study side effect anidulafungin see well work prevent fungal infection immunocompromised child neutropenia cause chemotherapy aplastic anemia .</brief_summary>
	<brief_title>Anidulafungin Treating Immunocompromised Children With Neutropenia</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety , tolerability , pharmacokinetics anidulafungin immunocompromised child neutropenia . - Determine frequency deeply invasive fungal infection child receive drug early empirical therapy . OUTLINE : This dose-escalation , open-label , multicenter study . Patients assign 1 2 group accord age ( 2 11 year vs 12 17 year ) . Patients receive anidulafungin IV daily 45-120 minute . In group , cohort 6 patient receive escalate dos anidulafungin . Treatment continue 28 day patient recover neutropenia become eligible standard empirical antifungal therapy absence unacceptable toxicity breakthrough fungal infection . Patients follow 7-9 day . PROJECTED ACCRUAL : A total 25 patient ( approximately 12 per group ) accrue study .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Neutropenia due cytotoxic chemotherapy aplastic anemia Duration expect 10 day Absolute neutrophil count le 500/mm^3 OR less 1,000/mm^3 expect fall 500/mm^3 within 72 hour No deeply invasive fungal infection confirm prior study entry PATIENT CHARACTERISTICS : Age 2 17 Performance status Not specify Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic AST ALT great 5 time upper limit normal ( ULN ) Bilirubin great 2.5 time ULN Renal Creatinine clearance least 30 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 30 day study participation No prior anaphylaxis attribute echinocandin class antifungals No concurrent medical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 4 week since prior investigational drug No prior participation clinical trial No prior anidulafungin No concurrent investigational drug No concurrent systemic antifungal agent ( e.g. , amphotericin , systemic azoles , triazole antifungal agent ) Concurrent oral , nonabsorbable azoles topical antifungal agent ( e.g. , nystatin and/or azole formulation ) allow Concurrent broadspectrum antibiotic allow</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>infection</keyword>
	<keyword>neutropenia</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>